| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kruppel-Like Transcription Factors | 14 | 2018 | 280 | 3.070 |
Why?
|
| Pancreatic Neoplasms | 27 | 2024 | 5233 | 2.010 |
Why?
|
| Carcinoma, Pancreatic Ductal | 12 | 2024 | 1817 | 1.970 |
Why?
|
| Hyaluronan Receptors | 4 | 2024 | 250 | 1.210 |
Why?
|
| Acinar Cells | 2 | 2019 | 55 | 1.160 |
Why?
|
| Pancreatic Ducts | 2 | 2019 | 128 | 1.110 |
Why?
|
| Sp1 Transcription Factor | 14 | 2011 | 193 | 1.100 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2024 | 13 | 0.930 |
Why?
|
| Naphthalenes | 1 | 2024 | 84 | 0.890 |
Why?
|
| PPAR delta | 5 | 2023 | 53 | 0.860 |
Why?
|
| Stomach Neoplasms | 18 | 2023 | 2317 | 0.810 |
Why?
|
| Gene Expression Regulation, Neoplastic | 22 | 2018 | 9078 | 0.750 |
Why?
|
| Neoplastic Stem Cells | 6 | 2024 | 1469 | 0.700 |
Why?
|
| Proto-Oncogenes | 1 | 2018 | 208 | 0.620 |
Why?
|
| Neovascularization, Pathologic | 12 | 2011 | 1599 | 0.590 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 82 | 0.580 |
Why?
|
| Pancreas | 4 | 2022 | 744 | 0.580 |
Why?
|
| Cell Dedifferentiation | 1 | 2017 | 101 | 0.560 |
Why?
|
| Carcinogenesis | 5 | 2023 | 1030 | 0.530 |
Why?
|
| Pancreatitis | 1 | 2019 | 292 | 0.530 |
Why?
|
| Animals | 55 | 2024 | 62759 | 0.510 |
Why?
|
| Mice | 47 | 2024 | 35990 | 0.510 |
Why?
|
| Forkhead Transcription Factors | 7 | 2015 | 774 | 0.500 |
Why?
|
| Gastric Mucosa | 7 | 2019 | 659 | 0.490 |
Why?
|
| Cell Line, Tumor | 28 | 2024 | 14864 | 0.490 |
Why?
|
| Liver Neoplasms | 9 | 2023 | 4787 | 0.480 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2023 | 2159 | 0.470 |
Why?
|
| Gene Silencing | 1 | 2017 | 834 | 0.470 |
Why?
|
| Neoplasm Metastasis | 17 | 2017 | 5324 | 0.460 |
Why?
|
| Receptors, Calcitriol | 3 | 2023 | 150 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factor A | 12 | 2011 | 1603 | 0.410 |
Why?
|
| DNA-Binding Proteins | 6 | 2005 | 5042 | 0.410 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2018 | 1885 | 0.400 |
Why?
|
| Promoter Regions, Genetic | 16 | 2016 | 3245 | 0.400 |
Why?
|
| Precancerous Conditions | 2 | 2016 | 1066 | 0.390 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 2399 | 0.380 |
Why?
|
| Protein Isoforms | 3 | 2018 | 860 | 0.360 |
Why?
|
| Mice, Nude | 22 | 2016 | 4360 | 0.350 |
Why?
|
| Adenocarcinoma | 12 | 2023 | 7936 | 0.350 |
Why?
|
| Plicamycin | 5 | 2011 | 30 | 0.350 |
Why?
|
| Tumor Cells, Cultured | 8 | 2019 | 5834 | 0.340 |
Why?
|
| Nitric Oxide Synthase | 4 | 2005 | 329 | 0.330 |
Why?
|
| Mice, Inbred BALB C | 14 | 2016 | 2474 | 0.320 |
Why?
|
| Transcription Factors | 5 | 2006 | 5494 | 0.300 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2008 | 298 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2019 | 2471 | 0.290 |
Why?
|
| Neoplasms | 7 | 2018 | 15849 | 0.280 |
Why?
|
| Signal Transduction | 12 | 2020 | 12205 | 0.280 |
Why?
|
| Heat-Shock Proteins | 2 | 2024 | 340 | 0.270 |
Why?
|
| Humans | 61 | 2024 | 270856 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5517 | 0.270 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 673 | 0.270 |
Why?
|
| Blotting, Western | 14 | 2016 | 3648 | 0.260 |
Why?
|
| Nitric Oxide | 3 | 2005 | 664 | 0.260 |
Why?
|
| Wnt Signaling Pathway | 2 | 2020 | 443 | 0.250 |
Why?
|
| Electrophoretic Mobility Shift Assay | 5 | 2008 | 201 | 0.240 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 641 | 0.240 |
Why?
|
| Disease Models, Animal | 10 | 2024 | 7461 | 0.230 |
Why?
|
| beta Catenin | 2 | 2020 | 690 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2024 | 3920 | 0.220 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 178 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 11761 | 0.220 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 3 | 2008 | 31 | 0.210 |
Why?
|
| Cell Proliferation | 7 | 2024 | 7294 | 0.210 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2014 | 316 | 0.210 |
Why?
|
| Trans-Activators | 3 | 2005 | 1655 | 0.210 |
Why?
|
| Up-Regulation | 6 | 2016 | 2465 | 0.210 |
Why?
|
| Mucin-1 | 1 | 2023 | 164 | 0.210 |
Why?
|
| Heterografts | 4 | 2017 | 745 | 0.200 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 236 | 0.200 |
Why?
|
| Immunohistochemistry | 16 | 2015 | 7809 | 0.200 |
Why?
|
| Lymphokines | 1 | 2003 | 318 | 0.200 |
Why?
|
| Alternative Splicing | 2 | 2018 | 612 | 0.200 |
Why?
|
| Neoplasms, Experimental | 2 | 2011 | 791 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2018 | 10698 | 0.190 |
Why?
|
| Glycolysis | 2 | 2014 | 533 | 0.190 |
Why?
|
| Glutamine | 1 | 2023 | 329 | 0.190 |
Why?
|
| Immediate-Early Proteins | 1 | 2001 | 109 | 0.190 |
Why?
|
| Forkhead Box Protein M1 | 7 | 2015 | 114 | 0.190 |
Why?
|
| Down-Regulation | 6 | 2017 | 2109 | 0.190 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2020 | 20 | 0.180 |
Why?
|
| Adenosine Triphosphatases | 1 | 2023 | 428 | 0.180 |
Why?
|
| Linoleic Acid | 1 | 2020 | 29 | 0.180 |
Why?
|
| Gamma Rays | 1 | 2001 | 241 | 0.180 |
Why?
|
| Blotting, Northern | 6 | 2008 | 736 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 624 | 0.180 |
Why?
|
| Models, Animal | 1 | 2003 | 675 | 0.170 |
Why?
|
| Transfection | 10 | 2020 | 3169 | 0.170 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2008 | 1268 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1408 | 0.170 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 163 | 0.170 |
Why?
|
| Ceruletide | 1 | 2019 | 28 | 0.170 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 495 | 0.160 |
Why?
|
| Survival Analysis | 5 | 2018 | 9305 | 0.160 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 203 | 0.150 |
Why?
|
| Cytokines | 2 | 2019 | 2836 | 0.150 |
Why?
|
| Cell Cycle | 3 | 2010 | 2151 | 0.150 |
Why?
|
| Cell Transdifferentiation | 1 | 2019 | 117 | 0.150 |
Why?
|
| Colonic Neoplasms | 2 | 2020 | 1437 | 0.150 |
Why?
|
| Metaplasia | 1 | 2019 | 386 | 0.140 |
Why?
|
| Transcriptional Activation | 3 | 2014 | 1147 | 0.140 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 217 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 8 | 2019 | 4067 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 8 | 2020 | 7216 | 0.140 |
Why?
|
| Cell Growth Processes | 3 | 2009 | 339 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 4 | 2014 | 512 | 0.140 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 152 | 0.140 |
Why?
|
| RNA, Small Interfering | 7 | 2016 | 2214 | 0.140 |
Why?
|
| Transplantation, Heterologous | 4 | 2014 | 1089 | 0.140 |
Why?
|
| Disease Progression | 11 | 2019 | 6890 | 0.140 |
Why?
|
| Stomach | 1 | 2019 | 406 | 0.130 |
Why?
|
| Female | 36 | 2020 | 148467 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 6 | 1 | 2015 | 6 | 0.130 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2016 | 65 | 0.130 |
Why?
|
| Neurofibromin 2 | 1 | 2015 | 42 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 1984 | 0.130 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 5161 | 0.130 |
Why?
|
| Tissue Array Analysis | 5 | 2015 | 759 | 0.120 |
Why?
|
| Genes, Reporter | 1 | 2017 | 831 | 0.120 |
Why?
|
| Gene Expression | 4 | 2017 | 3680 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2019 | 1184 | 0.120 |
Why?
|
| Lymphatic Metastasis | 8 | 2012 | 4967 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2004 | 1919 | 0.120 |
Why?
|
| Transcription, Genetic | 7 | 2016 | 3415 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2018 | 688 | 0.120 |
Why?
|
| Prognosis | 12 | 2015 | 22456 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 1547 | 0.110 |
Why?
|
| Microfilament Proteins | 2 | 2019 | 496 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2003 | 4182 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2015 | 4509 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2024 | 1777 | 0.110 |
Why?
|
| Neoplasm Transplantation | 4 | 2010 | 1567 | 0.110 |
Why?
|
| Smad4 Protein | 1 | 2014 | 200 | 0.110 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 2984 | 0.110 |
Why?
|
| Genes, ras | 1 | 2016 | 680 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2017 | 2906 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 14678 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1820 | 0.100 |
Why?
|
| Isoenzymes | 3 | 2014 | 663 | 0.100 |
Why?
|
| Stem Cells | 1 | 2019 | 1230 | 0.100 |
Why?
|
| Inflammation | 2 | 2019 | 2526 | 0.100 |
Why?
|
| Pyloric Antrum | 1 | 2011 | 77 | 0.100 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 1432 | 0.100 |
Why?
|
| Indoles | 1 | 2017 | 1035 | 0.100 |
Why?
|
| Chemokine CCL20 | 2 | 2023 | 39 | 0.100 |
Why?
|
| Cell Division | 3 | 2011 | 2716 | 0.100 |
Why?
|
| Nucleoside Deaminases | 2 | 2001 | 45 | 0.100 |
Why?
|
| Triterpenes | 1 | 2011 | 68 | 0.090 |
Why?
|
| Cell Nucleus | 3 | 2007 | 1742 | 0.090 |
Why?
|
| Mutation | 3 | 2024 | 15841 | 0.090 |
Why?
|
| Protein Binding | 6 | 2020 | 3536 | 0.090 |
Why?
|
| Caveolin 1 | 1 | 2011 | 204 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 1019 | 0.090 |
Why?
|
| Cell Movement | 5 | 2016 | 2500 | 0.090 |
Why?
|
| RNA Interference | 4 | 2016 | 1398 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2004 | 1119 | 0.080 |
Why?
|
| Apoptosis | 5 | 2024 | 7847 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 3349 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2005 | 255 | 0.080 |
Why?
|
| Glucose | 1 | 2014 | 1249 | 0.080 |
Why?
|
| Immunoprecipitation | 3 | 2016 | 594 | 0.070 |
Why?
|
| Adenoviridae | 3 | 2005 | 1510 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 704 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 3653 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 704 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 3657 | 0.070 |
Why?
|
| HCT116 Cells | 2 | 2019 | 354 | 0.070 |
Why?
|
| Cell Differentiation | 3 | 2015 | 4190 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 1212 | 0.070 |
Why?
|
| Mutagenesis | 1 | 2008 | 524 | 0.070 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2007 | 69 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5411 | 0.070 |
Why?
|
| Middle Aged | 16 | 2020 | 90016 | 0.070 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2005 | 26 | 0.070 |
Why?
|
| Drug Synergism | 4 | 2011 | 1369 | 0.060 |
Why?
|
| Molecular Chaperones | 1 | 2006 | 269 | 0.060 |
Why?
|
| Point Mutation | 1 | 2008 | 791 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2008 | 909 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2018 | 3532 | 0.060 |
Why?
|
| Genetic Therapy | 3 | 2001 | 1732 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2020 | 6483 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2019 | 5836 | 0.060 |
Why?
|
| Neoplasm Staging | 7 | 2014 | 13976 | 0.060 |
Why?
|
| Flucytosine | 2 | 2001 | 33 | 0.060 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2017 | 1004 | 0.060 |
Why?
|
| Hep G2 Cells | 2 | 2015 | 147 | 0.060 |
Why?
|
| Receptors, CCR6 | 1 | 2023 | 24 | 0.060 |
Why?
|
| Celecoxib | 1 | 2004 | 203 | 0.060 |
Why?
|
| Response Elements | 1 | 2004 | 200 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2004 | 261 | 0.050 |
Why?
|
| Carcinogenicity Tests | 1 | 2003 | 69 | 0.050 |
Why?
|
| Male | 16 | 2020 | 128412 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2005 | 589 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2016 | 1214 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2003 | 250 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 3 | 2005 | 1146 | 0.050 |
Why?
|
| Caspases | 1 | 2005 | 698 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2016 | 4985 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2024 | 226 | 0.050 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2017 | 104 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2003 | 351 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2005 | 1045 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2003 | 249 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2004 | 360 | 0.050 |
Why?
|
| Time Factors | 6 | 2014 | 13110 | 0.050 |
Why?
|
| Interleukin-18 | 1 | 2001 | 91 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2001 | 66 | 0.050 |
Why?
|
| Exons | 1 | 2005 | 1379 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2003 | 624 | 0.050 |
Why?
|
| Thymidine Kinase | 1 | 2001 | 224 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2007 | 5086 | 0.050 |
Why?
|
| Osteoblasts | 1 | 2003 | 394 | 0.050 |
Why?
|
| Antimetabolites | 1 | 2000 | 77 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5781 | 0.040 |
Why?
|
| RNA Stability | 1 | 2020 | 133 | 0.040 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2000 | 191 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 1061 | 0.040 |
Why?
|
| Kidney | 1 | 2008 | 2260 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2019 | 68 | 0.040 |
Why?
|
| Cell Survival | 3 | 2014 | 3081 | 0.040 |
Why?
|
| DNA Primers | 3 | 2006 | 1508 | 0.040 |
Why?
|
| Methylation | 1 | 2020 | 626 | 0.040 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2020 | 221 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2019 | 194 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 16593 | 0.040 |
Why?
|
| Sulfones | 1 | 2019 | 149 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 293 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 1132 | 0.040 |
Why?
|
| Arginine | 1 | 2020 | 509 | 0.040 |
Why?
|
| Macrophages | 1 | 2003 | 1368 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2016 | 106 | 0.030 |
Why?
|
| Fatty Liver | 1 | 2018 | 257 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2016 | 233 | 0.030 |
Why?
|
| Aged | 8 | 2020 | 73160 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2019 | 706 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 1654 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2018 | 244 | 0.030 |
Why?
|
| BALB 3T3 Cells | 1 | 2014 | 5 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2004 | 1542 | 0.030 |
Why?
|
| Tumor Burden | 2 | 2012 | 2034 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2018 | 374 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2005 | 2736 | 0.030 |
Why?
|
| Thiazoles | 1 | 2019 | 729 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2017 | 531 | 0.030 |
Why?
|
| Tyrosine | 1 | 2016 | 510 | 0.030 |
Why?
|
| Genetic Vectors | 3 | 2005 | 1884 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 5105 | 0.030 |
Why?
|
| Bevacizumab | 2 | 2008 | 959 | 0.030 |
Why?
|
| Transduction, Genetic | 2 | 2006 | 496 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2014 | 320 | 0.030 |
Why?
|
| Antigens, CD34 | 2 | 2005 | 642 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1883 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 1045 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2018 | 748 | 0.030 |
Why?
|
| Microbiota | 1 | 2019 | 541 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 4371 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2020 | 1726 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2016 | 1834 | 0.030 |
Why?
|
| Methylnitrosourea | 1 | 2011 | 51 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 15247 | 0.020 |
Why?
|
| Phenotype | 3 | 2011 | 6464 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2017 | 1482 | 0.020 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2011 | 15 | 0.020 |
Why?
|
| Cytosine Deaminase | 2 | 2001 | 43 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 16186 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 1744 | 0.020 |
Why?
|
| Laminin | 1 | 2011 | 212 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 744 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2011 | 278 | 0.020 |
Why?
|
| ortho-Aminobenzoates | 1 | 2010 | 20 | 0.020 |
Why?
|
| Integrases | 1 | 2011 | 266 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 573 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2011 | 634 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2014 | 1377 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3083 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 738 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1441 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 2306 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2024 | 4983 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2008 | 3395 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2490 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 1666 | 0.020 |
Why?
|
| DNA | 2 | 2004 | 3072 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 1333 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 451 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6248 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 278 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 4109 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 956 | 0.010 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2003 | 28 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 10249 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2003 | 126 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2004 | 364 | 0.010 |
Why?
|
| Osteogenesis | 1 | 2003 | 264 | 0.010 |
Why?
|
| Oncogenes | 1 | 2004 | 700 | 0.010 |
Why?
|
| China | 1 | 2003 | 642 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 613 | 0.010 |
Why?
|
| Retroviridae | 1 | 2001 | 376 | 0.010 |
Why?
|
| Survival Rate | 2 | 2005 | 12516 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 5495 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 2288 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 6784 | 0.010 |
Why?
|
| Genome | 1 | 2003 | 683 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2001 | 812 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 10349 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 4331 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 3492 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 4983 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 5492 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 5435 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 9042 | 0.010 |
Why?
|
| Adult | 2 | 2006 | 81545 | 0.000 |
Why?
|
| Melanoma | 1 | 2004 | 5523 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 30941 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2004 | 33819 | 0.000 |
Why?
|